. Author manuscript; available in PMC: 2014 May 20.

Published in final edited form as: Eur Neuropsychopharmacol. 2012 Oct 22;23(8):931–940. doi: 10.1016/j.euroneuro.2012.09.008

Table 2.

Baseline scores on SOPS and MADRS measures.

Domain	Study Treatment Measure	Open-label Glycine (n = 10) Mean (SD)	Double-blind
Domain	Study Treatment Measure	Open-label Glycine (n = 10) Mean (SD)	Glycine (n=4) Mean (SD)	Placebo (n=4) Mean (SD)
Prodromal symptoms	SOPS total	39.7 (11.8)	37.8 (15.3)	37.5 (10.0)
	SOPS positive	11.3 (3.3)	14.8 (2.2)	13.0 (2.8)
	SOPS negative	12.4 (5.5)	11.0 (8.0)	11.0 (7.2)
	SOPS disorganization	6.5 (2.5)	6.3 (3.1)	4.0 (1.2)
	SOPS general	9.5 (4.1)	5.8 (5.7)	9.5 (3.4)
Depression	MADRS total	13.8 (6.7)^a	13.0 (14.7)	17.3 (7.0)

n=9.